Associated Genetic Biomarkers
Cyclin B3 (CCNB3) is a gene that encodes a member of the cyclin family that functions as a regulator of cyclin-dependent kinases (CDKs). Cyclin B3 is involved in the regulation of the cell cycle. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, lung cancer, and skin cancer.
CCNB3 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CCNB3 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with CCNB3 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is CCNB3 Mutation .
Abemaciclib is the most frequent therapy in trials with CCNB3 as an inclusion criteria .
Significance of CCNB3 in Diseases
Malignant Solid Tumor +
CCNB3 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNB3 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.